Cite
HARVARD Citation
Dörner, T. et al. (2019). Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Annals of the rheumatic diseases. 78 (5), pp. 641-647. [Online].